To address the existing deficiencies in the knowledge regarding liver involvement and spectrum of clinical presentation and the impact of COVID-19 infection in patients of liver disease was planned. The present study will be a hospital based and the cases of confirmed COVID-19 infection will be evaluated in relation to liver involvement irrespective of pre-existing liver disease. The primary objective was to address the clinical presentation, biochemical alteration and outcomes of COVID-19 infection in subjects with chronic hepatitis, cirrhosis in comparison to those having infection in the absence of pre-existing liver disease
Study Type
OBSERVATIONAL
Enrollment
1,000
no intervention
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
RECRUITINGSpontaneous recovery or death in both groups
Time frame: 90 days
Severity of prior as well as present decompensation in both groups
Time frame: 90 days
Duration of prior as well as present decompensation in both groups
Time frame: 90 days
Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups
Time frame: 90 days
Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups
Time frame: 90 days
Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups
Time frame: 90 days
Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups
Time frame: 90 days
Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.